The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1497158
Abstract: ABSTRACT Introduction: Type 2 diabetes (T2D), a multifactorial and chronic disease, requires in an elevated percentage of patients the association of several antidiabetic drugs to achieve optimal glycemic control. Dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium–glucose… read more here.
Keywords: combination; inhibitor; combination therapies; safety ... See more keywords